IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rickey et al.

Appl. No. 09/263,098

Filed: March 5, 1999

For: Preparation of Biodegradable

Biocompatible Micropatibles
Containing a Biologically Active

Agent

Art Unit: 1615

Examiner: C. Azpuru

Atty. Docket: 00166.0063.US04

Terminal Disclaimer to Obviate a Double Patenting Rejection Under 37 C.F.R. § 1.321(c)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Alkermes Controlled Therapeutics Inc. II ("Alkermes") represents that it is the owner of the entire right, title, and interest of Application No. 09/071,865, filed on May 4, 1998, and U.S. Patent No. 5,916,598 that issued therefrom, by virtue of an Assignment from all of the inventors thereof executed on July 27 and July 28, 1998, recorded on October 1, 1998 at Reel 9501, Frame 0123. Said assignment also covers all continuations from Application No. 09/071,865. As the above-named Application No. 09/263,098, is a continuation of Application No. 09/071,865, Alkermes is the owner of the entire right, title, and interest of the above-named Application No. 09/263,098 by virtue of the assignment recorded at Reel 9501, Frame 0123.

Alkermes represents that it is a co-owner of the entire right, title, and interest of Application No. 08/850,679, filed on May 2, 1997, and U.S. Patent No. 5,792,477 that issued therefrom, by virtue of an Assignment of inventors thereof recorded on November 14, 1997 at Reel 8808, Frame 0012.

Establishing Right of Assignee to Take Action Under 37 C.F.R. § 3.73(b)

A Certificate Under 37 C.F.R. § 3.73(b) establishing the right to act on behalf of the assignee, with regard to the above-identified application is being filed herewith.

Disclaimer

Alkermes hereby disclaims the terminal part of any patent granted on the aboveidentified application that would extend beyond the expiration of its co-owned U.S. Patent No. 5,792,477 and hereby agrees that any patent granted on the above-identified application, or any patent granted on the above-identified application and subject to the reexamination proceeding, shall be enforceable only for and during such period that said patent is commonly owned with the application or patent that formed the basis of the obviousness type double patenting rejection, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the aboveidentified application prior to the expiration date of the full statutory term, as currently shortened by any terminal disclaimer, of Patent No. 5,792,477 in the event that Patent No. 5,792,477 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by terminal disclaimer, except for the separation of legal title stated above.

This disclaimer is accompanied by the fee set forth in 37 C.F.R. § 1.20(d).

Respectfully submitted,

Name

Title VICE PRESIDENT

Alkermes Controlled Therapeutics Inc. II

Date: 3-21-00

Certificate Under 37 C.F.R. § 3.73(b)

Applicar	nts: <u>Mich</u>	ael E. Ricke	y; J. Michael Ra	amstack;	and Danny H. Lewis	(APR 0 4 2000 🖏	
Application No: <u>09/263,098</u>							TRADOMENT S	
					icroparticles Containir	ag a Piolo	ricelly Active Agent	
1 01. <u>1 10</u>	paration	or Blodegra	dable, blocompa	atioic ivi	icroparticles Containi	ig a biolo	gicany Active Agent	
Alkermes Controlled Therapeutics Inc. II (Name of Assignee)					, a Corporation (Type of Assignee, e.g., corporation, partnership, university, government agency.etc.)			
states tha		e assignee of	f the entire right,	, title and	d interest in the patent	applicatio	n identified above by	
	An Assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel <u>9501</u> , Frame <u>0123</u> , or for which a copy thereof is attached.							
	A chain of title from the inventor(s) of the patent application identified above to the current assignee as shown below: 1. From: To: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.							
	2. From:	The docum	ent was recorded	d in the l	Patent and Trademark, or for which a cop	Office at	is attached.	
	3. From:	The docum	ent was recorded	d in the l	Patent and Trademark, or for which a cop	Office at	is attached.	
	[] Addi	itional docur	nents in the chai	in of title	e are listed on a supple	emental she	eet.	
[] Copie	es of assi	ignments or	other documents	s in the c	hain of title are attach	ed.		
	est of the identifie		d's knowledge ar	nd belief	title of the patent app	olication ic	lentified above is in the	
The unde	ersigned	(whose title	is supplied below	w) is em	powered to act on beh	alf of the	assignee.	
informat that willf 1001, Ti	ion and t ful false s tle 18 of	pelief are bel statements, a	lieved to be true; and the like so m States Code, and	; and fur ade, are	ther, that these stateme punishable by fine or	ents are m imprisonn	at all statements made on ade with the knowledge nent, or both under Section opardize the validity of the	
Date: _			3-21-00					
Name: _	5	au -	JAMES	TR	ATES			
Title:								
Signature	e:	aws	tros					